First EMEA Licensed Treatment Specifically For LGS Offers New Hope For Patients With Epilepsy
Jun 1st 2008Drug InformationEpilepsy
Eisai Europe Limited, (Headquarters: London, Chairman and CEO Yutaka Tsuchiya) today announced publication of the results of a major study of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome (LGS), a severe form of generalised epilepsy that develops in early childhood.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
